149 related articles for article (PubMed ID: 29341428)
1. Epigenetic Silencing of TAP1 in Aldefluor
Sultan M; Vidovic D; Paine AS; Huynh TT; Coyle KM; Thomas ML; Cruickshank BM; Dean CA; Clements DR; Kim Y; Lee K; Gujar SA; Weaver ICG; Marcato P
Stem Cells; 2018 May; 36(5):641-654. PubMed ID: 29341428
[TBL] [Abstract][Full Text] [Related]
2. The influence of TAP1 and TAP2 gene polymorphisms on TAP function and its inhibition by viral immune evasion proteins.
Praest P; Luteijn RD; Brak-Boer IGJ; Lanfermeijer J; Hoelen H; Ijgosse L; Costa AI; Gorham RD; Lebbink RJ; Wiertz EJHJ
Mol Immunol; 2018 Sep; 101():55-64. PubMed ID: 29879547
[TBL] [Abstract][Full Text] [Related]
3. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
Al-Dhfyan A; Alhoshani A; Korashy HM
Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884
[TBL] [Abstract][Full Text] [Related]
4. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis.
Johnsen AK; Templeton DJ; Sy M; Harding CV
J Immunol; 1999 Oct; 163(8):4224-31. PubMed ID: 10510359
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer stem-like cells can promote metastasis by activating platelets and down-regulating antitumor activity of natural killer cells.
Wang S; Zhang Y; Cong W; Liu J; Zhang Y; Fan H; Xu Y; Lin H
J Tradit Chin Med; 2016 Aug; 36(4):530-7. PubMed ID: 28459521
[TBL] [Abstract][Full Text] [Related]
6. Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype.
Reuben JM; Lee BN; Gao H; Cohen EN; Mego M; Giordano A; Wang X; Lodhi A; Krishnamurthy S; Hortobagyi GN; Cristofanilli M; Lucci A; Woodward WA
Eur J Cancer; 2011 Jul; 47(10):1527-36. PubMed ID: 21334874
[TBL] [Abstract][Full Text] [Related]
7. DNA methyltransferase 1 is essential for initiation of the colon cancers.
Morita R; Hirohashi Y; Suzuki H; Takahashi A; Tamura Y; Kanaseki T; Asanuma H; Inoda S; Kondo T; Hashino S; Hasegawa T; Tokino T; Toyota M; Asaka M; Torigoe T; Sato N
Exp Mol Pathol; 2013 Apr; 94(2):322-9. PubMed ID: 23064049
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Wnt1 expression reduces the enrichment of cancer stem cells in a mouse model of breast cancer.
Choi AR; Park JR; Kim RJ; Kim SR; Cho SD; Jung JY; Nam JS
Biochem Biophys Res Commun; 2012 Aug; 425(2):436-42. PubMed ID: 22846569
[TBL] [Abstract][Full Text] [Related]
9. Inhibitor of DNA-binding 4 contributes to the maintenance and expansion of cancer stem cells in 4T1 mouse mammary cancer cell line.
Park SJ; Kim RJ; Nam JS
Lab Anim Res; 2011 Dec; 27(4):333-8. PubMed ID: 22232642
[TBL] [Abstract][Full Text] [Related]
10. Dietary compound isoliquiritigenin prevents mammary carcinogenesis by inhibiting breast cancer stem cells through WIF1 demethylation.
Wang N; Wang Z; Wang Y; Xie X; Shen J; Peng C; You J; Peng F; Tang H; Guan X; Chen J
Oncotarget; 2015; 6(12):9854-76. PubMed ID: 25918249
[TBL] [Abstract][Full Text] [Related]
11. Isolation of stem cells from human pancreatic cancer xenografts.
Rasheed Z; Wang Q; Matsui W
J Vis Exp; 2010 Sep; (43):. PubMed ID: 20972397
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
[TBL] [Abstract][Full Text] [Related]
13. Breast Tumor Cells Highly Resistant to Drugs Are Controlled Only by the Immune Response Induced in an Immunocompetent Mouse Model.
Lasso P; Llano Murcia M; Sandoval TA; Urueña C; Barreto A; Fiorentino S
Integr Cancer Ther; 2019; 18():1534735419848047. PubMed ID: 31056957
[TBL] [Abstract][Full Text] [Related]
14. Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer.
Duhachek-Muggy S; Qi Y; Wise R; Alyahya L; Li H; Hodge J; Zolkiewska A
Mol Cancer; 2017 Feb; 16(1):32. PubMed ID: 28148288
[TBL] [Abstract][Full Text] [Related]
15. Caveolin-1 mediates chemoresistance in breast cancer stem cells via β-catenin/ABCG2 signaling pathway.
Wang Z; Wang N; Li W; Liu P; Chen Q; Situ H; Zhong S; Guo L; Lin Y; Shen J; Chen J
Carcinogenesis; 2014 Oct; 35(10):2346-56. PubMed ID: 25085904
[TBL] [Abstract][Full Text] [Related]
16. HOXC8 regulates self-renewal, differentiation and transformation of breast cancer stem cells.
Shah M; Cardenas R; Wang B; Persson J; Mongan NP; Grabowska A; Allegrucci C
Mol Cancer; 2017 Feb; 16(1):38. PubMed ID: 28202042
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors.
Barbieri F; Thellung S; Ratto A; Carra E; Marini V; Fucile C; Bajetto A; Pattarozzi A; Würth R; Gatti M; Campanella C; Vito G; Mattioli F; Pagano A; Daga A; Ferrari A; Florio T
BMC Cancer; 2015 Apr; 15():228. PubMed ID: 25884842
[TBL] [Abstract][Full Text] [Related]
18. Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma.
Geng S; Guo Y; Wang Q; Li L; Wang J
Arch Dermatol Res; 2013 Jan; 305(1):35-47. PubMed ID: 22740085
[TBL] [Abstract][Full Text] [Related]
19. Transporter associated with antigen processing 1 (TAP1) expression and prognostic analysis in breast, lung, liver, and ovarian cancer.
Tabassum A; Samdani MN; Dhali TC; Alam R; Ahammad F; Samad A; Karpiński TM
J Mol Med (Berl); 2021 Sep; 99(9):1293-1309. PubMed ID: 34047812
[TBL] [Abstract][Full Text] [Related]
20. Immune evasion by cancer stem cells.
Tsuchiya H; Shiota G
Regen Ther; 2021 Jun; 17():20-33. PubMed ID: 33778133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
